Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada

Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22325838

DOI
10.1016/j.ejca.2012.01.012

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Angiogenesis Inhibitors /economics /therapeutic use; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /economics; Bevacizumab; British Columbia; Colorectal Neoplasms /drug therapy /economics /mortality /pathology; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Neoplasm Metastasis; Quality-Adjusted Life Years; Sensitivity and Specificity

AccessionNumber
22012032343

Date bibliographic record published
04/01/2013